N6, A Novel, Broad, Highly Potent HIV-specific Antibody

This is a new antibody coming out of NIAID ’s intramural program. N6 has evolved a unique mode of binding that depends less on a variable area of the HIV envelope known as the V5 region and focuses more on conserved regions, which change relatively little among HIV strains. This allows N6 to tolerate changes in the HIV envelope, including the attachment of sugars in the V5 region, a major mechanism by which HIV develops resistance to other VRC01-class antibodies. N6 was shown in pre-clinical studies to neutralize 98 percent of HIV isolates tested. The studies also demonstrate that N6 neutralizes 80 percent of HIV isolates which we re resistant to other antibodies of the same class, and does so very potently. Its breadth and potency makes N6 a highly desirable candidate for development in therapeutic or prophylactic strategies.IC: NIAIDNIH Ref. No.: E-131-2015/0Advantages: Neutralized 98 percent of HIV isolates testedNeutralized 80 percent of HIV isolates which were resistant to other antibodies of the same class, and does so very potentlyApplications: HIV therapeuticHIV prophylacticProvider Technology ID: 3114Updated On: Mar 15, 2017Date Published: Wednesday, March 15, 2017Provider Classifications: Patent Application: 62/136,22862/250,378PCT/US2016/023145Publications: Patent Authority: USUSPCTLicensing Contacts: Lead Inventor: Inventor IC: NIAIDNIAIDNIAIDNIAIDNIAIDNIAIDNIAIDNIAIDInventor Lab URL: ht...

Source: NIH OTT Licensing Opportunities - March 15, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research